ArticleJournal of translational medicine2011
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?
Article in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach.Life sciences · 2020Review
- Vitamin C alleviates acute enterocolitis in Campylobacter jejuni infected mice.Scientific reports · 2020Article
- Immunomodulatory and Antimicrobial Effects of Vitamin C.European journal of microbiology & immunology · 2019Review
- Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications.International journal of molecular sciences · 2018Review
- Antioxidant treatment with vitamin C attenuated rotator cuff degeneration caused by oxidative stress inJSES open access · 2018Article
- Phytotherapy and Nutritional Supplements on Breast Cancer.BioMed research international · 2017Review
- HIF-1α restricts NF-κB-dependent gene expression to control innate immunity signals.Disease models & mechanisms · 2015Article
- Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.Journal of translational medicine · 2014Review
- Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice.International journal of oncology · 2013Article
- Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.